Detection of IL-17A and IL-17F gene polymorphism in recurrent and disseminated pityriasis versicolor: a case-control

S R El-Tahlawi1, A H Ramadan1, O G Shaker2

  • 1Department of Dermatology, Kasr Al Ainy Teaching Hospital, Faculty of Medicine, Cairo University, Al-Saray Street, Kasr Al Ainy, El Manial, Cairo, 11956, Egypt.

Insights

Genetic variations in Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F) genes are linked to an increased risk of developing recurrent and disseminated pityriasis versicolor (RDPV). This finding highlights a potential genetic predisposition to the fungal skin infection.

Area of Science:

  • Medical Mycology
  • Human Genetics
  • Immunology

Background:

  • Recurrent and disseminated pityriasis versicolor (RDPV) presents a significant clinical challenge due to its persistent and disfiguring nature.
  • Previous research indicates that host genetic factors, particularly those influencing the immune response, play a role in susceptibility to fungal infections, with a notable focus on Interleukin-17 (IL-17).

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms of IL-17A and IL-17F and the occurrence of RDPV.
  • To determine if these genetic variations contribute to the risk of developing RDPV.

Main Methods:

  • A case-control study involving 100 patients diagnosed with RDPV and 100 age- and sex-matched healthy controls.
  • Single-nucleotide polymorphism (SNP) analysis was performed on EDTA blood samples to genotype IL-17A (rs2275913) and IL-17F (rs763780).

Main Results:

  • The study found a statistically significant association between IL-17A (rs2275913) and IL-17F (rs763780) gene polymorphisms and an increased incidence of RDPV.
  • These specific polymorphisms were identified as risk factors for the development of RDPV.

Conclusions:

  • IL-17A and IL-17F gene polymorphisms are implicated as genetic risk factors for recurrent and disseminated pityriasis versicolor.
  • Understanding these genetic predispositions may offer insights into the pathogenesis and potential future therapeutic targets for RDPV.